You do not have permission to access this chart.
Please Sign Up or Login

About:

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen’s University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

206

Address:

ERYTECH Pharma S.A. 60 Avenue Rockefeller Lyon 69008 France

Website:

Home

Phone:

33 4 78 74 44 38

Leave a comment

Your email address will not be published. Required fields are marked *